165 related articles for article (PubMed ID: 30099215)
21. [Medication of the month. Exforge HCT: combination of amlodipine besylate, valsartan and hydrochlorothiazide in a single tablet].
Lancellotti P
Rev Med Liege; 2010; 65(7-8):471-5. PubMed ID: 20857707
[TBL] [Abstract][Full Text] [Related]
22. Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control.
Lawrence Gould A; Unniachan S; Wu D
Int J Clin Pract; 2014 Feb; 68(2):163-72. PubMed ID: 24460615
[TBL] [Abstract][Full Text] [Related]
23. Electrospun amorphous solid dispersions of poorly water-soluble drugs: A review.
Yu DG; Li JJ; Williams GR; Zhao M
J Control Release; 2018 Dec; 292():91-110. PubMed ID: 30118788
[TBL] [Abstract][Full Text] [Related]
24. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
Lee HY; Kang HJ; Koo BK; Oh BH; Heung-Sun K; Kim KS; Seo HS; Ro YM; Kang JH; Woong CJ; Joo SJ; Kim MH; Joon-Han S; Yoon J; Park SH; Jin-Ok J; Ju AK; Chong-Yun R; Yeon KJ; Park KM; Lim DK; Park SY;
Clin Ther; 2005 Jun; 27(6):728-39. PubMed ID: 16117979
[TBL] [Abstract][Full Text] [Related]
25. Stability of amlodipine besylate and atenolol in multi-component tablets of mono-layer and bi-layer types.
Aryal S; Skalko-Basnet N
Acta Pharm; 2008 Sep; 58(3):299-308. PubMed ID: 19103566
[TBL] [Abstract][Full Text] [Related]
26. Hybrid Electrospun Polycaprolactone Mats Consisting of Nanofibers and Microbeads for Extended Release of Dexamethasone.
Hsu KH; Fang SP; Lin CL; Liao YS; Yoon YK; Chauhan A
Pharm Res; 2016 Jun; 33(6):1509-16. PubMed ID: 26975358
[TBL] [Abstract][Full Text] [Related]
27. Continuous manufacturing and analytical characterization of fixed-dose, multilayer orodispersible films.
Thabet Y; Lunter D; Breitkreutz J
Eur J Pharm Sci; 2018 May; 117():236-244. PubMed ID: 29499348
[TBL] [Abstract][Full Text] [Related]
28. Carrier particle mediated stabilization and isolation of valsartan nanoparticles.
Kumar A; Davern P; Hodnett BK; Hudson SP
Colloids Surf B Biointerfaces; 2019 Mar; 175():554-563. PubMed ID: 30579056
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Solvent Casting and Spray Casting Method on Compounding of an Orally Disintegrating Film Containing Amlodipine Besylate.
Ruslan MFH; Janakiraman AK; Ming LC; Uddin AH; Sarker ZI; Bin LK
Int J Pharm Compd; 2022; 26(2):155-162. PubMed ID: 35413014
[TBL] [Abstract][Full Text] [Related]
30. Design and stability study of an oral solution of amlodipine besylate for pediatric patients.
van der Vossen AC; van der Velde I; Smeets OS; Postma DJ; Vermes A; Koch BC; Vulto AG; Hanff LM
Eur J Pharm Sci; 2016 Sep; 92():220-3. PubMed ID: 27217083
[TBL] [Abstract][Full Text] [Related]
31. Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.
Li DX; Yan YD; Oh DH; Yang KY; Seo YG; Kim JO; Kim YI; Yong CS; Choi HG
Drug Deliv; 2010 Jul; 17(5):322-9. PubMed ID: 20367177
[TBL] [Abstract][Full Text] [Related]
32. A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
Ulusoy S; Ozkan G; Konca C; Kaynar K
Hypertens Res; 2012 Nov; 35(11):1111-7. PubMed ID: 22786565
[TBL] [Abstract][Full Text] [Related]
33. Bioequivalence evaluation of two amlodipine salts, besylate and orotate, each in a fixed-dose combination with olmesartan in healthy subjects.
Lee SY; Kim JR; Jung JA; Huh W; Bahng MY; Ko JW
Drug Des Devel Ther; 2015; 9():2811-7. PubMed ID: 26082611
[TBL] [Abstract][Full Text] [Related]
34. The impact of chirality on the development of robust and stable tablet formulation of (S-) amlodipine besylate.
Hadžidedić S; Uzunović A; Sehić Jazić S; Kocova El-Arini S
Pharm Dev Technol; 2014 Dec; 19(8):930-41. PubMed ID: 24099553
[TBL] [Abstract][Full Text] [Related]
35. Development of Water-Soluble Electrospun Fibers for the Oral Delivery of Cannabinoids.
Andriotis EG; Chachlioutaki K; Monou PK; Bouropoulos N; Tzetzis D; Barmpalexis P; Chang MW; Ahmad Z; Fatouros DG
AAPS PharmSciTech; 2021 Jan; 22(1):23. PubMed ID: 33400042
[TBL] [Abstract][Full Text] [Related]
36. Nebulization performance of biodegradable sildenafil-loaded nanoparticles using the Aeroneb Pro: formulation aspects and nanoparticle stability to nebulization.
Beck-Broichsitter M; Kleimann P; Gessler T; Seeger W; Kissel T; Schmehl T
Int J Pharm; 2012 Jan; 422(1-2):398-408. PubMed ID: 22001839
[TBL] [Abstract][Full Text] [Related]
37. Development of Oromucosal Dosage Forms by Combining Electrospinning and Inkjet Printing.
Palo M; Kogermann K; Laidmäe I; Meos A; Preis M; Heinämäki J; Sandler N
Mol Pharm; 2017 Mar; 14(3):808-820. PubMed ID: 28195483
[TBL] [Abstract][Full Text] [Related]
38. Antihypertensive nano-ceuticales based on chitosan biopolymer: Physico-chemical evaluation and release kinetics.
Niaz T; Shabbir S; Manzoor S; Rehman A; Rahman A; Nasir H; Imran M
Carbohydr Polym; 2016 May; 142():268-74. PubMed ID: 26917399
[TBL] [Abstract][Full Text] [Related]
39. A new strategy for taste masking on bitter drug by other combined drug in fixed-dose combination: bitterness of Amlodipine besylate could be masked efficiently by Valsartan.
Kojima H; Nakamura S; Haraguchi T; Yoshida M; Habara M; Ikezaki H; Uchida T
J Pharm Pharmacol; 2019 Sep; 71(9):1384-1392. PubMed ID: 31273801
[TBL] [Abstract][Full Text] [Related]
40. Fixed Dose Single Tablet Formulation with Differential Release of Amlodipine Besylate and Simvastatin and Its Pharmacokinetic Profile: QbD and Risk Assessment Approach.
Kanwal U; Mukhtar S; Waheed M; Mehreen A; Abbas N; Shamim R; Hussain K; Rasool F; Hussain A; Bukhari NI
Drug Des Devel Ther; 2021; 15():2193-2210. PubMed ID: 34079222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
